



Cathryn Fuller  
Project Manager  
National Institute of Clinical Excellence  
MidCity Place  
71 High Holborn  
London  
WC1V 6NA

24<sup>th</sup> October 2005

Dear Cathryn,

**Re: NICE appraisal consultation document on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women and comments on NICE appraisal consultation document on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.**

Thank you for the opportunity to comment appraisal consultation document for the above appraisals. The BSR has seen and strongly supports the response made by the National Osteoporosis Society.

Please do contact Karishma Chandaria, Policy Officer at BSR if you require any further information from the society.

Yours sincerely

Chief Executive